annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
8:00 AM - 12:00 PM
GENERAL POSTER SESSION
Lung Cancer—Metastatic
Location: S Hall A2
Tracks(s): Lung Cancer
Brd. 31A A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G)
weekly followed by erlotinib (E) after progression versus erlotinib followed
by docetaxel/gemcitabine after progression in advanced non-small cell lung
cancer (NSCLC) in fit elderly patients selected with a comprehensive
geriatric assessment (CGA): Groupe Français de Pneumocancerologie
(GFPC)*0504 (Abstract #7536)
H. Le Caer, F. Barlesi, R. Corre, H. Jullian, S. Bota, L. Falchero, A. Vergnenegre,
C. Dujon, J. Y. Delhoume, C. Chouaid
Brd. 31B Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human
epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI),
as first-line treatment (tx) of selected patients (pts) with advanced (adv)
non-small cell lung cancer (NSCLC). (Abstract #7537)
T. Mok, D. R. Spigel, K. Park, M. A. Socinski, S. Y. Tung, D. Kim, G. Borzillo,
H. Zhang, J. P. O’Connell, P. A. Janne
Brd. 31C EGFR and ABCG2 polymorphisms as prognostic and predictive markers in
the NCIC CTG BR.21 trial of single-agent erlotinib in advanced non-small cell
lung cancer (NSCLC). (Abstract #7538)
G. Liu, D. Cheng, A. Le Maitre, N. Liu, Z. Chen, L. Seymour, K. Ding,
F. A. Shepherd, M. S. Tsao
Brd. 32A Clinical impact of amphiregulin expression in EGFR wild-type non-small cell
lung cancer patients treated with EGFR tyrosine kinase inhibitors. (Abstract
#7539)
M. Chang, J. Lee, C. Jung, Y. Park, J. Ahn, K. Park, M. Ahn
Brd. 32B Biomarker analyses from a phase l study of pertuzumab combined with
erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).
(Abstract #7540)
E. Felip, M. Ranson, S. Cedres, M. Brewster, V. Mcnally, M. Venturi,
A. Passioukov, G. Ross, D. Galdermans
Brd. 32C Association of KRAS and EGFR mutations with survival in patients with
advanced lung adenocarcinoma. (Abstract #7541)
M. L. Johnson, C. Sima, P. K. Paik, Y. Y. Janjigian, W. Pao, M. G. Kris, M. Ladanyi,
G. J. Riely
Brd. 33A EGFR mutation status and survival after diagnosis of brain metastasis in
non-small cell lung cancer. (Abstract #7542)
A. F. Eichler, K. T. Kahle, D. L. Wang, V. A. Joshi, J. A. Engelman, L. V. Sequist
Brd. 33B Rates of CNS progression in patients with advanced NSCLC harboring
somatic EGFR mutations and treated with gefitinib or erlotinib.
(Abstract #7543)
S. Heon, B. Y. Yeap, G. J. Britt, M. S. Rabin, D. M. Jackman, B. E. Johnson
Brd. 33C Clinicopathologic differences between lung cancer with EGFR gene major
(exon 19 deletions and exon 21 L858R) and other minor mutations.
(Abstract #7544)
Y. Yamane, K. Goto, H. Kenmotsu, Y. Ohe, H. Ohmatsu, S. Niho, K. Yoh, G. Ishii,
K. Nagai, Y. Nishiwaki
Brd. 34A The usefulness of 18 f-fluorothymidine (FLT) and 18 F-FDG PET for early
prediction of response to erlotinib therapy in patients with advanced nonsmall
cell lung cancer. (Abstract #7545)
C. Choi, K. Shin, D. Lee, S. Oh, J. Kim, D. Moon, C. Suh, J. Ryu, S. Kim
214